Nicox–Leerink: investor conference, 201702 supply service Nicox presents at Leerink Partners Global Healthcare Conference in NYC

	Period	2017-02-16
	Region	New York, NY
	Country	United States (USA)
	Partner, 1st	Nicox S.A. (Euronext Paris: COX)
	Group	Nicox (Group)
	Partner, 2nd	Leerink Partners LLC [old]
	Today	Leerink Partners (Group)
	Group	Leerink Partners (Group)
	Product	Leerink Partners Annual Global Healthcare Conference 2017 New York
	Product 2	ophthalmic
	Person	Garufi, Michele (NicOx 200809 Chairman + CEO)

Nicox S.A.. (2/9/17). "Press Release: Nicox to Present at the 6th Annual Leerink Partners Global Healthcare Conference". Sophia Antipolis.

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the 6th Annual LEERINK Partners Global Healthcare Conference on Thursday, February 16th, 2017 at 3:00 p.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel.

A live webcast of the presentation will be available on the Company's website (www.nicox.com) in "Presentations & Events". A replay of the webcast will be archived on the Nicox website for 90 days following the date of the presentation.

Michele Garufi will also be available for one-on-one meetings at the conference.

About Nicox

Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma. Nicox currently has two products at the pre-approval stage with the U.S. Food and Drug Administration (FDA) and a promising pipeline including next-generation stand-alone nitric-oxide donors, with the potential to treat a range of ophthalmic indications. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com .

Analyst coverage

Bryan, Garnier & Co Hugo Solvet Paris, France
Invest Securities Martial Descoutures Paris, France
Gilbert Dupont Damien Choplain Paris, France
Stifel Olivia Manser London, UK

Upcoming financial and business conferences

March 6-8 Cowen and Company 37th Annual Health Care Conference Boston, US
March 21-22 Oppenheimer 27th Annual Healthcare Conference New York, US
April 4-5 Needham's 16th Annual Healthcare Conference New York, US
May 3-4 Deutsche Bank 42nd Annual Health Care Conference Boston, US
May 30 Gilbert Dupont 15th Annual Healthcare Conference Paris, France
June 19-22 2017 BIO International Convention San Diego, US

Contacts

Nicox
Gavin Spencer,
Executive Vice President Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com

Investor Relations
Europe
NewCap
Julien Perez, Valentine Brouchot
T +33 (0)1 44 71 94 94
nicox@newcap.eu

Media Relations
United Kingdom
Jonathan Birt
T +44 7860 361 746
jonathan.birt@ymail.com

United States
Argot Partners
Melissa Forst
T +1 (212) 600-1902
melissa@argotpartners.com

France
NewCap
Nicolas Merigeau
T +33 (0)1 44 71 94 98
nicox@newcap.eu

United States
Argot Partners
Eliza Schleifstein
T +1 (917) 763-8106
eliza@argotpartners.com

Disclaimer

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99